Crohn’s Disease (IL-23 Study)

Study Drug: Biological therapy involving already registered drugs from the IL-23 antagonist and IL-1 antagonist groups, which will be administered alone (monotherapy) or in combination with an experimental drug from the anti-a4B7 mAb group.

Study Drug: Patients will receive either standard biological therapy (adalimumab) or experimental biological therapy with an IL-1 proinflammatory molecule blocker.

Study Drug: Experimental biological therapy that blocks the effect of the pro-inflammatory molecule TL1A.

Study Drug: Patients will receive standard biological therapy with vedolizumab or vedolizumab biosimilar.